Actively Recruiting
Non-invasive Vagus Nerve Stimulation (nVNS) for Post-Traumatic Stress Disorder (PTSD)
Led by Acacia Clinics · Updated on 2026-04-27
40
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
A
Acacia Clinics
Lead Sponsor
E
ElectroCore INC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the safety and effectiveness of the gammaCore non-invasive vagus nerve stimulation (nVNS) device as an additional treatment for symptoms of post-traumatic stress disorder (PTSD) in adults. The vagus nerve connects the brain with many organs and systems in the body and plays a role in regulating stress and emotional responses. The gammaCore device is a handheld, rechargeable medical device that delivers gentle electrical stimulation to the vagus nerve through the skin on the side of the neck. By stimulating this nerve, the device may help reduce PTSD symptoms. gammaCore is cleared by the U.S. Food and Drug Administration (FDA) for the treatment and prevention of migraine and cluster headache. It has not yet been approved for the treatment of PTSD. This study is being conducted to better understand whether this type of stimulation may help improve PTSD symptoms and to evaluate its safety when used for this purpose. The main questions this study aims to answer are: * Is non-invasive vagus nerve stimulation safe for people with PTSD when used regularly at home? * Does treatment with the gammaCore device improve PTSD symptom severity over time? In this study, approximately 40 adults with PTSD will participate in an open-label pilot study. Participants will first complete a 4-week baseline period in which their PTSD symptoms are monitored. This allows researchers to understand each participant's symptoms before starting the intervention. Participants will then begin a 12-week treatment period using the gammaCore device at home. During this time, participants will apply the device to the side of the neck for short stimulation sessions each day as instructed by the study team. Participants will attend six study visits, some conducted remotely and some in person. These visits include screening, training on how to use the device, and follow-up assessments. During the study, participants will complete questionnaires and clinician-administered assessments that measure PTSD symptoms and quality of life. Researchers will also monitor participants for any side effects or medical problems related to the device. By collecting information on symptoms, safety, and device use, this study will help researchers understand whether non-invasive vagus nerve stimulation could become a useful treatment option for people living with PTSD.
CONDITIONS
Official Title
Non-invasive Vagus Nerve Stimulation (nVNS) for Post-Traumatic Stress Disorder (PTSD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of PTSD confirmed by the Structured Clinical Interview for DSM-5 (SCID)
- CAPS-5 score of 35 or higher
- Age between 18 and 70 years
- Presence of PTSD symptoms and either not taking PTSD medications or stable on PTSD medications for at least 3 months
- Agreement to avoid starting or changing certain medications that could interfere with study goals
- Willingness to use the nVNS device as instructed and attend follow-up visits
- Ability to provide written informed consent
- Must have a primary clinician responsible for psychiatric care before, during, and after the trial
You will not qualify if you...
- Psychiatric or cognitive disorders or behaviors that may interfere with the study, including suicidal or homicidal risk
- Major medical or neurological illnesses that interfere with the study based on physical exam or lab tests
- Cervical vagotomy or structural abnormalities at the treatment site on the neck
- Pain conditions at the treatment site such as dysesthesia or neuralgia
- Presence of implanted electrical or neurostimulator devices
- Pregnancy, planning to become pregnant, or unwillingness to use birth control if of childbearing age
- Belonging to a vulnerable population or conditions compromising informed consent or follow-up compliance
- History of stellate ganglion block (SGB)
- Employment by the investigator or clinical study site
- Recent or current use of rapid-acting antidepressants or other non-invasive stimulation therapies within 4 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Acacia Research Center
Sunnyvale, California, United States, 94087
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here